Viridiflorol Production in Auxotrophic E. coli
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The high cost and low enantioselectivity of chemical synthesis methods for viridiflorol limit its production yields, due to the complexity of synthesizing compounds with 6 chiral centers, making it challenging to produce this valuable fragrance molecule and antibacterial agent efficiently.
Innovation Solution
A method involving engineered host cells, such as E. coli, is developed, where a vector with an inducible promoter and optimized ribosomal binding site is used to increase translation initiation rate of the viridiflorol synthase enzyme, and specific inducer dosages are determined to enhance terpenoid production, including the introduction of mutations in the viridiflorol synthase enzyme and truncation of amino acids to improve enzyme activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If chemical synthesis methods are used for viridiflorol production, then the structural complexity of 6 chiral centers can be addressed, but the manufacturing precision and productivity are significantly reduced due to low enantioselectivity and ultra-high costs
Solution Approach 1:
The patent replaces chemical synthesis mechanisms with biological enzymatic mechanisms. Specifically, it uses terpene synthase enzymes (such as amorphadiene synthase or viridiflorol synthase) to catalyze the formation of viridiflorol from farnesyl diphosphate, substituting the mechanical/chemical synthesis approach with a biological catalytic approach that inherently provides enantioselectivity and simplifies the synthesis of compounds with multiple chiral centers
Solution Approach 2:
The patent optimizes various parameters including inducer dosage (such as IPTG concentration), induction time, temperature, and pH to maximize enzyme activity and viridiflorol production. It also modifies enzyme parameters through site-directed mutagenesis to improve catalytic efficiency and product yield, thereby resolving the productivity issue while maintaining enantioselectivity
2Reliability
If plant extracts are used as a source of viridiflorol, then natural production can be obtained, but the productivity is limited due to high cost and supply fluctuations
Solution Approach 1:
The patent uses engineered host cells (such as E. coli or yeast) as intermediaries to produce viridiflorol. These host cells are transformed with plasmids containing the terpene synthase gene and mevalonate pathway genes, serving as biological factories that convert simple precursors into viridiflorol, thereby eliminating dependence on plant extracts and ensuring stable supply
Solution Approach 2:
The patent employs self-service by using the host cell's own metabolic machinery (mevalonate pathway) to generate the necessary precursors (farnesyl diphosphate) for viridiflorol synthesis. The engineered cells autonomously produce all required components, eliminating the need for external plant extract supplementation and enabling scalable production
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach significantly increases viridiflorol production by optimizing gene expression and enzyme activity, achieving yields 2860-fold higher than initial methods, making the production more efficient and cost-effective.
Implementation Method 1
introduce an inducible promoter operably linked to the polynucleotide sequence encoding the terpene synthase enzyme
Implementation Method 2
introduce a polynucleotide sequence encoding a ribosomal binding site (RBS) that increases translation initiation rate of the terpenoid
Implementation Method 3
terpene synthases (TPSs), which convert acyclic prenyml diphosphate precursors into a multitude of cyclic and acyclic terpene scaffolds
Data Source
AI summary
A method of increasing terpenoid production in a host cell that produces one or more terpenoids, comprising: a) providing a host cell that produces one or more terpenoids, said host cell comprising a vector comprising a polynucleotide sequence encoding a terpene synthase enzyme; b) modifying the vector to:i. introduce an inducible promoter operably linked to the polynucleotide sequence encoding the terpene synthase enzyme; and ii. introduce a polynucleotide sequence encoding a ribosomal binding site (RBS) that increases translation initiation rate of the terpenoid compared to a wild type ribosomal binding site; c) determining the dosage of an inducer capable of inducing the inducible promoter; d) culturing the host cell in a culture medium in the presence of the inducer at the dosage determined from step c); and e) isolating the terpenoid from the culture medium.